FOLH1 and prostate carcinoma: In our opinion, prospective imaging studies are the key way towards exploring PSMA-RLT for non-prostate cancers, especially imaging studies in patients with advanced disease, as PSMA-RLT is likely to be explored in end-stage disease with limited other treatment options.